Discovering new products or re-evaluating existing ones so that patients and healthcare professionals have the best treatments is one of Eumedica's primary aims. Our research activity includes the following:

Rare infections

Certain bacteria which do not usually infect humans can nevertheless find a niche in some patients who are suffering from diseases which impair their defence capacities. Promising preliminary results have prompted us, in close collaboration with academics and patient associations, to study the efficacy of antibiotics against one of these rare infections to develop a new treatment.

Targeted antibiotherapy

The practical use of antibiotherapy is currently undergoing a change due to several factors, including the emergence of multi-resistant bacteria. Our studies with directed-spectrum drugs will allow us to offer new therapeutic regimens and therefore keep broad-spectrum antibiotics for infections where they remain the last effective ones. Moreover, when using directed-spectrum antibiotics, the bacterial ecology is also preserved.

Permeability of central catheters

In order to minimise the disadvantages of inopportune injections, some serious diseases (renal impairment, cancer, haemophilia etc.) require permanent access. This is particularly the case with children where fitting a catheter is always risky and painful. Unfortunately, these lines are easily blocked which prevents correct administration of the treatment and risks infections. In these cases, there is no alternative but to change the catheter. We are currently developing a substance which will save catheters by removing obstructions.

Additional information about our research will soon be available for healthcare professionals in the password-protected section Eumedica Pro.